Cellular resistance to mitomycin C is associated with overexpression of MDR‐1 in a urothelial cancer cell line (MGH‐U1)
Objective To compare multidrug resistance (MDR)‐1 and MDR‐3 gene expression in a new urothelial cancer cell line (MGHU‐1, with resistance to mitomycin C) against controls and the established (epirubicin‐resistant) MDR clone, and to correlate MDR with cytotoxicity data. Materials and methods Resistan...
Gespeichert in:
| Veröffentlicht in: | BJU international 2001-02, Vol.87 (3), p.245-250 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 250 |
|---|---|
| container_issue | 3 |
| container_start_page | 245 |
| container_title | BJU international |
| container_volume | 87 |
| creator | Hayes, M.C. Birch, B.R. Cooper, A.J. Primrose, J.N. |
| description | Objective To compare multidrug resistance (MDR)‐1 and MDR‐3 gene expression in a new urothelial cancer cell line (MGHU‐1, with resistance to mitomycin C) against controls and the established (epirubicin‐resistant) MDR clone, and to correlate MDR with cytotoxicity data.
Materials and methods Resistance to mitomycin C was induced by the long‐term exposure of wild‐type MGHU‐1 cells to increasing concentrations (20–400 nmol/L) of mitomycin C. The cytotoxicity of mitomycin C or epirubicin was then compared in MGHU‐1, MGHU‐MMC (mitomycin C‐resistant) and MGHU‐1R (established MDR) cells, using the tetrazolium biomass assay. The expression of MDR‐1 and ‐3 was investigated by the reverse transcriptase‐polymerase chain reaction, using cDNA‐specific primers after titration, and compared with DNA and negative controls.
Results MDR‐1 and ‐3 were significantly and equally overexpressed in MGHU‐1R, and associated with a dramatic increase in the 50% inhibitory drug concentration (P |
| doi_str_mv | 10.1046/j.1464-410x.2001.02027.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70651131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70651131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3937-8bfea5ddad1f23a6eb17ef9116b60f42804a3df40a14fe9627e3cba7172b0cfb3</originalsourceid><addsrcrecordid>eNqNkMFu1DAURa0K1JbSX0BeIASLSf0Sj5NIbGCAFtQKqepI3VmO86x65MSDndAZseET-Ea-BIeZii5Z-Uk-9137EEKBZcC4OFtlwAWfcWCbLGcMMpazvMw2B-T44eL2ycPManFEnsW4SiAXYn5IjgBAlGIOx-THAp0bnQo0YLRxUL1GOnja2cF3W217uqA2UhWj11YN2NJ7O9xR_x0DbtYpE63vqTf06sP175-_gKaEomPwwx06qxzV08ZAdaqhzvZIX1-dXyRyCW-ek6dGuYin-_OELD99vFlczC6_nn9evLuc6aIuylnVGFTztlUtmLxQAhso0dTpC41ghucV46poDWcKuMFa5CUWulEllHnDtGmKE_Jqt3cd_LcR4yA7G6cHqR79GGXJkgooIIHVDtTBxxjQyHWwnQpbCUxO4uVKTk7lJF5O4uVf8XKToi_2HWPTYfsvuDedgJd7QEWtnAnJi42PCoBVdZWwtzvs3jrc_ne_fP9lmYbiD5vOoWE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70651131</pqid></control><display><type>article</type><title>Cellular resistance to mitomycin C is associated with overexpression of MDR‐1 in a urothelial cancer cell line (MGH‐U1)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hayes, M.C. ; Birch, B.R. ; Cooper, A.J. ; Primrose, J.N.</creator><creatorcontrib>Hayes, M.C. ; Birch, B.R. ; Cooper, A.J. ; Primrose, J.N.</creatorcontrib><description>Objective To compare multidrug resistance (MDR)‐1 and MDR‐3 gene expression in a new urothelial cancer cell line (MGHU‐1, with resistance to mitomycin C) against controls and the established (epirubicin‐resistant) MDR clone, and to correlate MDR with cytotoxicity data.
Materials and methods Resistance to mitomycin C was induced by the long‐term exposure of wild‐type MGHU‐1 cells to increasing concentrations (20–400 nmol/L) of mitomycin C. The cytotoxicity of mitomycin C or epirubicin was then compared in MGHU‐1, MGHU‐MMC (mitomycin C‐resistant) and MGHU‐1R (established MDR) cells, using the tetrazolium biomass assay. The expression of MDR‐1 and ‐3 was investigated by the reverse transcriptase‐polymerase chain reaction, using cDNA‐specific primers after titration, and compared with DNA and negative controls.
Results MDR‐1 and ‐3 were significantly and equally overexpressed in MGHU‐1R, and associated with a dramatic increase in the 50% inhibitory drug concentration (P < 0.001) for mitomycin C and epirubicin against controls. In MGHU‐MMC, the overexpression of MDR‐1 was three times greater than that of MDR‐3. The cytotoxicity profile for both agents was very similar to that of MGHU‐1R. Trace amounts of MDR‐1, but not MDR‐3, were identified in the MGHU‐1 wild‐type.
Conclusions Urothelial cancer cell resistance to mitomycin C is associated with cross‐resistance to epirubicin and overexpression of MDR‐1, suggesting that mitomycin C falls within the MDR category. Clinical application of this methodology may allow patients to be identified who are unlikely to benefit from intravesical chemotherapy.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1046/j.1464-410x.2001.02027.x</identifier><identifier>PMID: 11167651</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Antibiotics, Antineoplastic - therapeutic use ; Antineoplastic agents ; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism ; Biological and medical sciences ; bladder cancer ; Chemotherapy ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Humans ; MDR‐1 ; Medical sciences ; Mitomycin - therapeutic use ; mitomycin C ; multidrug resistance ; Pharmacology. Drug treatments ; Tumor Cells, Cultured ; Urologic Neoplasms - drug therapy</subject><ispartof>BJU international, 2001-02, Vol.87 (3), p.245-250</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3937-8bfea5ddad1f23a6eb17ef9116b60f42804a3df40a14fe9627e3cba7172b0cfb3</citedby><cites>FETCH-LOGICAL-c3937-8bfea5ddad1f23a6eb17ef9116b60f42804a3df40a14fe9627e3cba7172b0cfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1464-410x.2001.02027.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1464-410x.2001.02027.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1010898$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11167651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayes, M.C.</creatorcontrib><creatorcontrib>Birch, B.R.</creatorcontrib><creatorcontrib>Cooper, A.J.</creatorcontrib><creatorcontrib>Primrose, J.N.</creatorcontrib><title>Cellular resistance to mitomycin C is associated with overexpression of MDR‐1 in a urothelial cancer cell line (MGH‐U1)</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Objective To compare multidrug resistance (MDR)‐1 and MDR‐3 gene expression in a new urothelial cancer cell line (MGHU‐1, with resistance to mitomycin C) against controls and the established (epirubicin‐resistant) MDR clone, and to correlate MDR with cytotoxicity data.
Materials and methods Resistance to mitomycin C was induced by the long‐term exposure of wild‐type MGHU‐1 cells to increasing concentrations (20–400 nmol/L) of mitomycin C. The cytotoxicity of mitomycin C or epirubicin was then compared in MGHU‐1, MGHU‐MMC (mitomycin C‐resistant) and MGHU‐1R (established MDR) cells, using the tetrazolium biomass assay. The expression of MDR‐1 and ‐3 was investigated by the reverse transcriptase‐polymerase chain reaction, using cDNA‐specific primers after titration, and compared with DNA and negative controls.
Results MDR‐1 and ‐3 were significantly and equally overexpressed in MGHU‐1R, and associated with a dramatic increase in the 50% inhibitory drug concentration (P < 0.001) for mitomycin C and epirubicin against controls. In MGHU‐MMC, the overexpression of MDR‐1 was three times greater than that of MDR‐3. The cytotoxicity profile for both agents was very similar to that of MGHU‐1R. Trace amounts of MDR‐1, but not MDR‐3, were identified in the MGHU‐1 wild‐type.
Conclusions Urothelial cancer cell resistance to mitomycin C is associated with cross‐resistance to epirubicin and overexpression of MDR‐1, suggesting that mitomycin C falls within the MDR category. Clinical application of this methodology may allow patients to be identified who are unlikely to benefit from intravesical chemotherapy.</description><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</subject><subject>Biological and medical sciences</subject><subject>bladder cancer</subject><subject>Chemotherapy</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Resistance, Neoplasm</subject><subject>Humans</subject><subject>MDR‐1</subject><subject>Medical sciences</subject><subject>Mitomycin - therapeutic use</subject><subject>mitomycin C</subject><subject>multidrug resistance</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Cells, Cultured</subject><subject>Urologic Neoplasms - drug therapy</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMFu1DAURa0K1JbSX0BeIASLSf0Sj5NIbGCAFtQKqepI3VmO86x65MSDndAZseET-Ea-BIeZii5Z-Uk-9137EEKBZcC4OFtlwAWfcWCbLGcMMpazvMw2B-T44eL2ycPManFEnsW4SiAXYn5IjgBAlGIOx-THAp0bnQo0YLRxUL1GOnja2cF3W217uqA2UhWj11YN2NJ7O9xR_x0DbtYpE63vqTf06sP175-_gKaEomPwwx06qxzV08ZAdaqhzvZIX1-dXyRyCW-ek6dGuYin-_OELD99vFlczC6_nn9evLuc6aIuylnVGFTztlUtmLxQAhso0dTpC41ghucV46poDWcKuMFa5CUWulEllHnDtGmKE_Jqt3cd_LcR4yA7G6cHqR79GGXJkgooIIHVDtTBxxjQyHWwnQpbCUxO4uVKTk7lJF5O4uVf8XKToi_2HWPTYfsvuDedgJd7QEWtnAnJi42PCoBVdZWwtzvs3jrc_ne_fP9lmYbiD5vOoWE</recordid><startdate>200102</startdate><enddate>200102</enddate><creator>Hayes, M.C.</creator><creator>Birch, B.R.</creator><creator>Cooper, A.J.</creator><creator>Primrose, J.N.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200102</creationdate><title>Cellular resistance to mitomycin C is associated with overexpression of MDR‐1 in a urothelial cancer cell line (MGH‐U1)</title><author>Hayes, M.C. ; Birch, B.R. ; Cooper, A.J. ; Primrose, J.N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3937-8bfea5ddad1f23a6eb17ef9116b60f42804a3df40a14fe9627e3cba7172b0cfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</topic><topic>Biological and medical sciences</topic><topic>bladder cancer</topic><topic>Chemotherapy</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Resistance, Neoplasm</topic><topic>Humans</topic><topic>MDR‐1</topic><topic>Medical sciences</topic><topic>Mitomycin - therapeutic use</topic><topic>mitomycin C</topic><topic>multidrug resistance</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Cells, Cultured</topic><topic>Urologic Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayes, M.C.</creatorcontrib><creatorcontrib>Birch, B.R.</creatorcontrib><creatorcontrib>Cooper, A.J.</creatorcontrib><creatorcontrib>Primrose, J.N.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayes, M.C.</au><au>Birch, B.R.</au><au>Cooper, A.J.</au><au>Primrose, J.N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cellular resistance to mitomycin C is associated with overexpression of MDR‐1 in a urothelial cancer cell line (MGH‐U1)</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2001-02</date><risdate>2001</risdate><volume>87</volume><issue>3</issue><spage>245</spage><epage>250</epage><pages>245-250</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>Objective To compare multidrug resistance (MDR)‐1 and MDR‐3 gene expression in a new urothelial cancer cell line (MGHU‐1, with resistance to mitomycin C) against controls and the established (epirubicin‐resistant) MDR clone, and to correlate MDR with cytotoxicity data.
Materials and methods Resistance to mitomycin C was induced by the long‐term exposure of wild‐type MGHU‐1 cells to increasing concentrations (20–400 nmol/L) of mitomycin C. The cytotoxicity of mitomycin C or epirubicin was then compared in MGHU‐1, MGHU‐MMC (mitomycin C‐resistant) and MGHU‐1R (established MDR) cells, using the tetrazolium biomass assay. The expression of MDR‐1 and ‐3 was investigated by the reverse transcriptase‐polymerase chain reaction, using cDNA‐specific primers after titration, and compared with DNA and negative controls.
Results MDR‐1 and ‐3 were significantly and equally overexpressed in MGHU‐1R, and associated with a dramatic increase in the 50% inhibitory drug concentration (P < 0.001) for mitomycin C and epirubicin against controls. In MGHU‐MMC, the overexpression of MDR‐1 was three times greater than that of MDR‐3. The cytotoxicity profile for both agents was very similar to that of MGHU‐1R. Trace amounts of MDR‐1, but not MDR‐3, were identified in the MGHU‐1 wild‐type.
Conclusions Urothelial cancer cell resistance to mitomycin C is associated with cross‐resistance to epirubicin and overexpression of MDR‐1, suggesting that mitomycin C falls within the MDR category. Clinical application of this methodology may allow patients to be identified who are unlikely to benefit from intravesical chemotherapy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11167651</pmid><doi>10.1046/j.1464-410x.2001.02027.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2001-02, Vol.87 (3), p.245-250 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70651131 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibiotics, Antineoplastic - therapeutic use Antineoplastic agents ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Biological and medical sciences bladder cancer Chemotherapy Drug Resistance, Multiple Drug Resistance, Neoplasm Humans MDR‐1 Medical sciences Mitomycin - therapeutic use mitomycin C multidrug resistance Pharmacology. Drug treatments Tumor Cells, Cultured Urologic Neoplasms - drug therapy |
| title | Cellular resistance to mitomycin C is associated with overexpression of MDR‐1 in a urothelial cancer cell line (MGH‐U1) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T03%3A47%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cellular%20resistance%20to%20mitomycin%20C%20is%20associated%20with%20overexpression%20of%20MDR%E2%80%901%20in%20a%20urothelial%20cancer%20cell%20line%20(MGH%E2%80%90U1)&rft.jtitle=BJU%20international&rft.au=Hayes,%20M.C.&rft.date=2001-02&rft.volume=87&rft.issue=3&rft.spage=245&rft.epage=250&rft.pages=245-250&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1046/j.1464-410x.2001.02027.x&rft_dat=%3Cproquest_cross%3E70651131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70651131&rft_id=info:pmid/11167651&rfr_iscdi=true |